Status: Recruiting
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Oana DanciuUpdated: Apr 8, 2026Locations: 20
Eligibility criteria
Written informed consent (stage I) and HIPAA authorization for release of person... [+38]
Patient with a known hypersensitivity to any of the excipients of ribociclib. [+20]